CMS Administrator Berwick Visits the Hill
This article was originally published in RPM Report
Medicare Part D and prescription drug prices come up briefly in a brief appearance by controversial CMS head Berwick before the Senate Finance Committee.
You may also be interested in...
There was probably no group more relieved than the makers of implantable cardioverter defibrillators (ICDs) to see the Centers for Medicaid and Medicare Services (CMS) in August drastically modify its proposal to slash hospital reimbursement. The change is as a result of effective lobbying from the medical device community as well as the hospital industry, and is welcome news to all high-end device makers.
The Centers for Medicare & Medicaid Services is showing a lot more interest in ensuring broad access to low-cost generic drugs now that the agency is overseeing the implementation of Medicare Part D. As evidence of this trend, CMS considered weighing in on a court decision regarding the availability of Zocoor generics.
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.